UMIN ID: UMIN000015951
Registered date:15/12/2014
1st line chemotherapy of XELoda/OXaliplatin for advanced Gastric cancer PI
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | gastric cancer |
| Date of first enrollment | 2014/12/07 |
| Target sample size | 9 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | capecitabine/oxaliplatin |
Outcome(s)
| Primary Outcome | safety |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | 1) active synchronous or metachronous malignancy other than carcinoma in situ 2) pregnant or nursing 3) severe mental disorders 4) systemic steroid user 5) diabetes mellitus, uncontrolled or controlled with insulin 6) history of myocardial infarction, unstable angina within 3 months prior to the registration 7) serious coexisting illness 8) active infection 9) peripheral neuropathy greater than Grade 2 10) ileus 11) massive pleural effusion or ascites |
Related Information
| Primary Sponsor | Kobe City Medical Center General Hospital |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Kobe City Medical Center General Hospital |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Hironaga Satake |
| Address | 2-1-1, Minatojima minamimachi,chuo-ku,Kobe city,Hyogo |
| Telephone | +81-(0)78-302-4321 |
| hsatake@kcho.jp | |
| Affiliation | Kobe City Medical Center General Hospital Division of Oncology / Gastroenterology, |
| scientific contact | |
| Name | Akihito Tsuji |
| Address | 2-1-1, Minatojima minamimachi,chuo-ku,Kobe city,Hyogo |
| Telephone | +81-(0)78-302-4321 |
| hsatake@kcho.jp | |
| Affiliation | Kobe City Medical Center General Hospital Division of Oncology |